PRODEGRE
Latest round
- Angel
Last raised
- Feb 2026
Total raised
- Undisclosed
Investors
- 1
About PRODEGRE
, trading as PRODEGRE, is a major neurological disease mechanism research and innovative drug development company. The company’s main business is the development of novel pharmaceuticals targeting major neurological diseases. The company’s self-developed products, leveraging a peptide-guided protein knockdown technology platform, are aimed at conditions such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The company generates revenues by providing research on the mechanisms of major neurological diseases and innovative medicines to the healthcare industry.
Who invested in PRODEGRE
1 investor across 1 round
See all investors in PRODEGRE
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Feb 25, 2026
Amount
Undisclosed
Investors
Questions about PRODEGRE
Who invested in PRODEGRE?
PRODEGRE has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has PRODEGRE raised?
PRODEGRE has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did PRODEGRE last raise money?
PRODEGRE's most recent round on record is a Angel, in Feb 2026.
What does PRODEGRE do?
, trading as PRODEGRE, is a major neurological disease mechanism research and innovative drug development company.
Where is PRODEGRE headquartered?
PRODEGRE is headquartered in Shanghai, China.
Which VCs invest in companies like PRODEGRE?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back pharmaceuticals companies at PRODEGRE's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Angel
Raising like PRODEGRE? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.